SCHEMBL23958586

SCHEMBL23958586

CC(C)(O)c1cc(C(O)(CN)C2CC2)nc(-c2ccc(F)cc2)c1Cl

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.33
CNR1 P21554 3/20 0.32
CNR2 P34972 3/20 0.32
SLC34A1 Q06495 1/20 0.31
CYP11B1 P15538 2/20 0.31
CYP11B2 P19099 2/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
P2RX7 Q99572 1/20 0.30
TNIK Q9UKE5 1/20 0.30
NR3C1 P04150 1/20 0.30
DPP4 P27487 1/20 0.30
ADRB1 P08588 1/20 0.30
ADRA2A P08913 1/20 0.30
CYP19A1 P11511 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25686936 1.00 CFTR (0.33) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL23958748 1.00 CFTR (0.33) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL25686955 0.89 CFTR (0.34) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL23958790 0.89 CFTR (0.34) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL23958632 0.89 CFTR (0.34) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL28909120 0.85 CYP11B1 (0.33) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL23958854 0.85 PRKACA (0.33) CNR1
SCHEMBL25686991 0.85 PRKACA (0.33) CNR1
SCHEMBL23930276 0.84 CFTR (0.36) CFTRCNR1CNR2SLC34A1CYP11B1
SCHEMBL23958821 0.84 CFTR (0.36) CFTRCNR1CNR2SLC34A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CFTR 508/4885CNR1 183/4885CNR2 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.